Solid Tumor Research Grant Scientific Focus (ACE)

The program is designed to support pre-clinical and clinical research in the field of Oncology Solid Tumors in Australia, Canada, and Europe. For the 2025 cycle, the program will focus on Breast, Upper GI (esophageal, gastric, & gastroesophageal junction cancer), and Lung cancer. Areas of research may include, but are not limited to:

Areas of research

Disparities and inequities in cancer care
Agnostic approaches to target solid tumors
Combinational drug strategies/approaches to treatment
Resistance mechanism identification/novel approaches to addressing resistance mechanisms
Transformative, therapeutic modalities/approaches to treatment
Patient-specific factors that are predictors of toxicity
Genomic polymorphisms and impact treatment response
Novel targets and/or biomarkers/imaging techniques
Novel diagnostic, prevention, and treatment strategies
Research to improve Quality of Life (QoL) Patient-Reported Outcomes (PRO's) e.g adverse events, addressing unmet needs for patients
Any other pre-clinical or clinical research that addresses an unmet medical need or gap in scientific knowledge

Requirements

Gilead Affiliated Products

Proposals utilizing Gilead product(s) are not eligible for funding through the Research Scholars Program. Proposals involving Gilead product(s) should be submitted for review under the Investigator-Sponsored Research Grant Program through the ISR online portal.

Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental, or industry sources. Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap in funding.

The Research Scholars Program is intended to support independent research by emerging investigators that is unrelated to Gilead’s strategies or priorities. However, all research projects selected by the Scientific Review Committee will need to be approved by an internal validation committee that, in rare circumstances, may be unable to support certain clinical interventional studies (e.g., studies focused solely on the safety and/or efficacy of non-Gilead products).

Proposals are reviewed by an independent Scientific Review Committee, (no Commercial involvement in review or selection, i.e., Marketing, Sales, and Commercial Strategy), and are reviewed based upon the criteria outlined on this website.

View Application Essentials to discover specific application details.

Application Essentials

Is the RSP award funded by the Gilead Foundation or the "For-Profit Company"?

The award is an industry sponsored award funded by Gilead Sciences, Inc. which is a for profit entity, not the Gilead Foundation. While the award is funded by Gilead Sciences, Inc., the review of the applications and selection of awardees is carried out by an independent scientific review committee. Gilead is not part of the scientific review committee and has no involvement in selecting the applications that receive the awards.

Does the stated approximate protected time need to be specific to this award, or can it be for research in general?

The approximate protected time refers to time spent on research in general. This time does not need to be spent only on research related to your RSP proposal.

Can I share the focus of my proposal to ensure the subject is something that would be appealing to the RSP committee for funding?

The approximate protected time refers to time spent on research in general. This time does not need to be spent only on research related to your RSP proposal.